Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder

Liu, Xiaohua; Zhang, Tianhong; Shen, He; Hong, Bo; Chen, Zheng; Peng, Daihui; Wu, Yan; Han, Wen; Lin, Zhiguang; Fang, Yiru; Jiang, Kaida

doi:10.1016/j.psychres.2014.03.042

Cited by 60 publications

(58 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the contrary, IGF-1 serum levels show an increase in many different psychiatric diseases (MDD, bipolar disorder, first-episode schizophrenia, and autism spectrum disorders), and recent papers also prove that IGF-1 levels are raised in neurological disorders such as Parkinson's disease, multiple system atrophy, etc. [9,10,11,12,13,14,44,45]. These findings suggest that IGF-1 elevation in mental disorders could exert counterregulatory neuroprotective effects.…”

Section: Discussionmentioning

confidence: 87%

“…These findings suggest that IGF-1 elevation in mental disorders could exert counterregulatory neuroprotective effects. In fact in these pathologies such an increase in the periphery might be a response to IGF-1 low bioavailability in the CNS [11,14]. IGF-1 serum content derived by liver synthesis might participate to a more complex mechanism - involving several key neurotrophic factors, such as BDNF - aimed at stimulating neural systems required for the reversal of damages induced by stress in general and by psychiatric disease in particular [25,46].…”

Section: Discussionmentioning

confidence: 99%

“…In this regard increased IGF-1 serum levels were observed in BD patients [48,49] and, in parallel, postmortem studies indicated a reduction of IGFBP-2 in patients' brains [50]. …”

Section: Discussionmentioning

confidence: 99%

“…IGF-1 may also modulate the receptor functions of neurotransmitters such as serotonin, noradrenaline, and dopamine, which are involved in the pathogenesis of many psychiatric disorders [8]. Many studies showed an increase of IGF-1 peripheral levels in different psychiatric diseases: major depressive disorder (MDD), bipolar disorder, and schizophrenia [7,9,10,11,12,13,14,15]. …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study

et al. 2016

View full text Add to dashboard Cite

Background/Aims: Recent findings suggest an involvement of insulin-like growth factor-1 (IGF-1) in the pathogenesis of many psychiatric disorders; however, there is a lack of data regarding IGF-1 in patients with obsessive-compulsive disorder (OCD). The aims of the present study were (1) to analyze putative alterations of IGF-1 serum content in patients with OCD compared to patients with major depressive disorder (MDD) and healthy controls, and (2) to analyze putative changes of IGF-1 levels during drug treatment in subjects with OCD compared to patients with MDD. Methods: We recruited 40 OCD patients, 37 MDD patients, and 43 healthy controls. All participants were adults. Serum IGF-1 levels were measured by the ELISA method on venous blood samples collected at baseline and after 10 ± 1 weeks of drug treatment. Results: IGF-1 levels were increased in OCD patients compared to controls (149.9 ± 60.2 vs. 121.2 ± 51.6 ng/ml; p = 0.040). No correlations were observed between baseline IGF-1 levels, clinical features, and response to treatment at follow-up in OCD or MDD patients. No changes in serum IGF-1 were observed after drug treatment. Conclusion: Our results show for the first time that serum IGF-1 levels are altered in patients with OCD. Further research on the role of IGF-1 in OCD is warranted.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

“…In this regard increased IGF-1 serum levels were observed in BD patients [48,49] and, in parallel, postmortem studies indicated a reduction of IGFBP-2 in patients' brains [50]. …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…There is ample evidence for involvement of prototype NGF and BDNF in development of schizophrenia (82)(83)(84), bipolar illness (37,85), depression (86,87), obsessive-compulsive disorder (OCD) (88)(89)(90), post traumatic stress disorder (PTSD) (91,92), eating disorders (93), conversion disorder (94), anxiety and aggression (57,83,95) and social defeat induced avoidance behaviour (77). Many studies reported NGFs' involvement in psychopathology of suicidal behaviour (96-98).…”

Section: Ngfs-a Common Link In Psychiatric Disordersmentioning

confidence: 99%

Nerve Growth Factor(s) Mediated Hypothalamic Pituitary Adrenal Axis Dysregulation Model in Stress Induced Genesis of Psychiatric Disorders

Kumar¹,

Kumar²,

Ma³

et al. 2017

Preprint

View full text Add to dashboard Cite

show abstract

Impact of maternal desvenlafaxine exposure on brain development in pregnant albino rats and their fetuses

Ahmed

Ghareeb

El‐Rahman

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Depression during pregnancy adversely affects fetal development. Desvenlafaxine drug is used for the treatment of gestational depression. In light of the well‐established role of brain‐derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in regulating neurogenesis and neural survival, the role of S100b in nerve cell energetic metabolism, differentiation of neurons and glial cells, an aberrant increase in NGF, BDNF and S100b expression in the fetal brain may contribute to desvenlafaxine cognitive disorders by altering brain development. This study is trying to determine the effect of desvenlafaxine on brain development. Thirty timed pregnant rats (from the 5th to the 20th day) were divided into three groups: control, low dose (5.14 mg/kg/day) and high dose (10.28 mg/kg/day) of desvenlafaxine where all animals received the corresponding doses by gavage. Maternal and fetal brain samples were fixed for histological, immunohistochemical (IHC) study of NGF and evaluated for BDNF and S100b genes expression. Desvenlafaxine induced some of the histopathological alterations in maternal and fetal rat brains. Moreover, IHC analysis of maternal and fetal rat brains showed that groups treated with desvenlafaxine demonstrated a significant increase of NGF protein immunoreactivity compared with that in the controls. Gene expression results revealed upregulation of messenger RNA BDNF and S100B expression. According to developmental changes in the brain, desvenlafaxine affects neonatal growth during pregnancy, which may lead to delay of brain development. So, it is essential to survey the roles of antidepressant drugs on neonatal development during pregnancy.

show abstract

Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder

Cited by 60 publications

References 53 publications

Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study

Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study

Nerve Growth Factor(s) Mediated Hypothalamic Pituitary Adrenal Axis Dysregulation Model in Stress Induced Genesis of Psychiatric Disorders

Impact of maternal desvenlafaxine exposure on brain development in pregnant albino rats and their fetuses

Contact Info

Product

Resources

About